pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1973 |
Genomic Coordinates | chr4: 116299725 - 116299768 |
Synonyms | hsa-mir-1973, MIR1973 |
Description | Homo sapiens miR-1973 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | |
---|---|
Mature miRNA | hsa-miR-1973 |
Sequence | 26| ACCGUGCAAAGGUAGCAUA |44 |
Evidence | Experimental |
Experiments | Cloned |
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ALS2CL | ||||||||||||||||||||
Synonyms | RN49018 | ||||||||||||||||||||
Description | ALS2 C-terminal like | ||||||||||||||||||||
Transcript | NM_001190707 | ||||||||||||||||||||
Other Transcripts | NM_147129 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ALS2CL | |||||||||||||||||||||
3'UTR of ALS2CL (miRNA target sites are highlighted) |
>ALS2CL|NM_001190707|3'UTR 1 CCTGGCCTTTCCTGGACAGACTGAAGAGCTGAGCAGGGCACTGCCAGCCTGTCCCTCATTACCCAAGGCAAGGGGCAGGA 81 CAGGCCCTCAGAAGCAGCTCTTGGAGGAGATGAGCATTTTGTTTTGCACAGGAAGATGCTGCTGCTGCCCTGACTGGGAT 161 GAGGGTGAGGGGTGACGGGTGTGGCCCTGGATGTGGTGGTTTTCCCTTGGCCACTAGCCCATCTTCAATGACCCCTTAAT 241 CTGCAGCAGCTCACAGGCTGGGGGTGAGGAGTCCCTGGCTTCTCTTAGCCTGAGCCTTTCTCCCAAGTTCCAGAGCCTCT 321 CCGGGCCTCAGTGCTGCCATCTGTACAATGGTGGAGTGAGTACGCTGTAAAGGACCTTCCATTCATTTTGCTGAATTCCA 401 GAGTCCTTTTGGAAAACTGACTTTAGTCTGCTGGGCTGTATTGACCTCTGGCAGGCTCGAAGCCTCACTGGGTATGCAGT 481 CAACAGGATGGGCCTGGAGATCCGTGAACTGCAGGCCACGTACCCATGACGTAAACGGCGGCACTGGAGCAAGCTGGGGC 561 GGGGGGTGGGTAAACCCTCACTGCCAGCAGGCCCCAAGTGGCTTGTAAATCATTCTCCTGTGATGTCTGTGGGCCTGCGT 641 GGGGACAACAGGGGCACATGACATCTGCCTGGGCCCTGACCAATAAACCCTCAGACCCAGGACCCAGGACCCTGCTGTAG 721 TTGGGGAGCAGGAGTACCTTTGGGAGGGGAGGACTTTATTTAAACAGTGGTTCTAGTGTGGGACCAAGAGAGGCAGGAGC 801 TGGGTCTTGGGGCAGCTTTATTCCTGTTGGGCCTCAGTTTCTCTTCCCCACACAGTTTATCTTCCGTCACATTGTGCCGG 881 GTGACGTGCACGGTCTCCCTCTGCCCTAGCCGGAGATGCATGATGACAGGCAGTGTGATGTGTTCTGAAAGTGTCCAGGG 961 CAAAGCGTAGGGAGAGGGTGGATTTGTGCAGGGTGCAGCTCTGGAGAAGAAGCTGGATCACTCTTGGTCCCATTCCCTAG 1041 GCCCTGAGCAAGTCAGGCTCCTGGCTCTGGGTGTGGCTCCCCCAAACGAAGTACTGACTTCAGCCTGTGAGGGGAGGGTT 1121 GAGGGAGGCTCTGGAAAGCCCAGCCACACCTGAGTCCCTGGCAGTAGCCTTGGGGCAGAGGGCACCCGCAGAGTCCCAGA 1201 GATGATGTGGGCAGTGGGCAGAGAGAGCCTTGGCGCCTCTGTTTGCCACCACTTCCCCAGGAAGGAGGGACAGCATTTCT 1281 CTGGCTGGTTCCACTAAATGTGCCAGCCCAAATGCAGGGCATGGGCTCTGGTTCTGCCAGGAGCCTGTGACACCCCCAGG 1361 AAGGGGGTGGAACTGAGGAAGAGCGAGGATATGCAGGCACTCATGCTTACCGGGACTGGGGCAGCTCACTAGGATTCTAT 1441 CCTTTCCAATCGGCATCAGCCAGCTCTTGTCCCCTGATAAGTGAGGACAGCCTGACCCTGGCCTCAAATGCAGCCATCCC 1521 TGAGTTCATGCGATGCTGACGGGACCCCAGCACACTTCCCTGCCTCCTTTGAGATCTGCGAGCCCTTGCTGCAGTTCAGA 1601 TTCAACAAGGCCCTCTGCCCACCCTCTCACTAGGCCTCACCCAACACCAGTGGAACTGGAGCCTCTGGCTGGGCACAGTG 1681 GCTCACTTTGGGAGGCTGAGGCAGGAAGGCTGCTGGAAACTGAGAGTTCAAGACCAGCCTGGGCAACATAGTGAGACCCT 1761 GTCTCTACAAATACAAAATAAAATAATTAGCTGGGTGTGTTGGTGTGTGCCTGTGGTCCCAGCTACTCGGGAGGCTGAGG 1841 TGGGAAGATCCCTGAGCCTGGAGGGTCGAGGTTGCAGTGAGCGGAGATCGCACCTCTGCACTCAATCCTGGGTGACAAAA 1921 TGAAACCCTGCCTCAAAAATAAAAATAAAAATAAAAATAAAATAAATAAAAAAGAGCATCTGGACAGAG Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | C8166 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462572. RNA binding protein: AGO2. Condition:C8166 NL4-3
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
CLIP-seq Support 1 for dataset GSM1462572 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | C8166 / C8166 NL4-3 |
Location of target site | ENST00000318962.4 | 3UTR | CGUGCACGGUCUCCCUC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
5 hsa-miR-1973 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT124152 | GINS4 | GINS complex subunit 4 | 2 | 4 | ||||||||
MIRT489630 | ALS2CL | ALS2 C-terminal like | 2 | 2 | ||||||||
MIRT492236 | SLC48A1 | solute carrier family 48 member 1 | 2 | 2 | ||||||||
MIRT566716 | MTFR1L | mitochondrial fission regulator 1 like | 2 | 2 | ||||||||
MIRT722042 | SSH3 | slingshot protein phosphatase 3 | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|